Do DNA kits provide actionable info for cancer, CVD, T2D, dementia, nutrition, or exercise? (AMA #8)

Attia has discussed Lp(a) extensively in prior episodes as an underrecognized cardiovascular risk driver. His point in this AMA is that the genetic test is redundant: if you measure the actual lipoprotein level, you already have the information that matters for clinical management. This is the cleanest example in the episode of his broader epistemological principle — phenotypic measurement beats genotypic prediction because it is more direct, equally accessible, and more actionable.

Attia positions the CGM as the metabolic equivalent of a liquid biopsy — a window into the actual physiology rather than the inherited template. His clinical argument is that detecting postprandial hyperinsulinemia and abnormal glucose disposal patterns years before overt T2D gives a long intervention window that genetic risk scores cannot provide. The CGM also generates feedback loops: patients see their glucose response to a specific meal or workout, which drives behavior change far more effectively than an abstract risk number from a genetic report.

Attia frames this as the phenotypic answer to the question 'what should I do about my T2D genetic risk?' The answer is: stop looking at the gene and start measuring the functional state of the metabolic system that gene predisposes you to. Fasting and postprandial insulin are the most direct read on pancreatic beta-cell compensation and peripheral insulin sensitivity. Combined with CGM data and ferritin patterns, they tell a complete story of where on the insulin resistance spectrum a patient sits — and therefore what interventions are indicated.

Attia describes APOE4 status as useful primarily for motivation rather than for changing the clinical approach — because the approach (optimize metabolic health, sleep, exercise, minimize head trauma) is identical regardless of genotype. The one novel application he flags is pediatric sport participation: APOE4's association with worse TBI outcomes suggests that APOE4-positive parents might reasonably steer children toward lower-contact sports like tennis rather than soccer or football. This is not a prohibition but a risk-weighting consideration.

Attia's argument is that even the emerging tests he considers potentially interesting — PPAR family genes that may speak to fat metabolism — require the empirical step anyway. So the genetic test does not save you from the experiment; it only possibly accelerates which hypothesis you test first. Given the cost, inaccuracy of consumer SNP kits, and the fact that the empirical test is needed regardless, the genetic starting point adds minimal value. This is the 'empirical step' principle that runs through his entire genetics take: phenotype always trumps genotype for clinical decision-making.

Attia's broader point is that for the general non-adopted population, the high-penetrance syndromes are almost always already known from the family tree — the clinical presentation in first- and second-degree relatives makes them apparent before any genetic test. But the adopted patient has no family tree to read. For them, genetic testing serves a function it cannot serve for the typical patient: revealing inherited risk that has no other data source. This is also the one context in Attia's clinic where a genetic test has changed clinical management for a patient.

Attia draws a sharp line between two mutation types: germline (inherited, present in every cell, readable by any DNA test) and somatic (acquired during life, present only in the mutant cells, detectable only by searching the blood for circulating tumor cells or cell-free DNA). Liquid biopsy companies are building exactly that technology — blood tests that can theoretically find a single mutant colon cell circulating in the bloodstream, identify its tissue of origin, and characterize its escape mutations. But this is emphatically not what a 23andMe or comparable SNP test does. The rare exceptions are high-penetrance germline syndromes: BRCA mutations (up to ~80% lifetime breast/ovarian cancer risk depending on variant) and Lynch syndrome (near-certain colorectal and other cancers). Importantly, Attia notes that for non-adopted individuals who know their family history, these syndromes are usually already apparent without a genetic test — the family tree tells the story first.

Attia makes two concrete arguments for APOE4 testing. First, motivational leverage: if a patient is already doing everything right, knowing they carry APOE4 may push them to be even more rigorous about sleep, exercise, metabolic health, and cardiovascular optimization — all known Alzheimer's risk modifiers. Second, pediatric sport decisions: APOE4 status appears to increase susceptibility to the neuroinflammatory sequelae of repeated head trauma, so an APOE4-positive parent might reasonably choose tennis over soccer for their child. He is careful to add that even without APOE4, the preventive imperative is unchanged: as neurologist Richard Isaacson told him, 'if you have a brain you're at risk of Alzheimer's disease.'

Attia has discussed Lp(a) at length in prior episodes as an underappreciated atherosclerotic driver, particularly for early or aggressive coronary artery disease. His point here is epistemological: the purpose of genetic information is to change management, and if the phenotypic test (a direct blood Lp(a) measurement) already delivers the exact number that would change management, the genetic test is redundant. This applies more broadly to his whole stance on genetics versus phenotypics — the phenotype is almost always more actionable because you can track it, intervene, and re-measure.

Attia's clinical reasoning: a genetic flag says 'you are predisposed' but gives no time reference, no severity signal, and no intervention target. Postprandial hyperinsulinemia, by contrast, is detectable years before fasting glucose or HbA1c moves, is quantifiable with a simple insulin challenge, and directly tells you both the severity of the defect and which interventions (dietary carbohydrate reduction, exercise timing, metformin) to consider first. A CGM adds continuous, real-world glycemic data across meals, sleep, and exercise — a richer signal than any static genetic flag by orders of magnitude.

Attia frames this as context-setting before addressing the specific diseases in the question. His point: even if you sequence every base pair correctly (which cheap SNP kits do not), the information would still be limited because common diseases do not work like Huntington's or BRCA. They are not single-gene disorders with deterministic penetrance. They are probability distributions across hundreds of variants, each contributing a few percent of variance, all of which interact with diet, exercise, sleep, stress, and metabolic state. This is also why Attia's clinical philosophy centers on phenotypic measurement — because the phenotype integrates both the genetic predisposition and the environmental modulation into a single readable signal.